Metacognitive Therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with Obsessive-Compulsive Disorder (OCD)

Iranian Journal of Psychiatry and Behavioral Sciences

Volumn 4, Issue 2, 2010, Pages 17-25

  Shareh, Hossein ^a,b   Gharraee, Banafsheh ^a,b   Atef Vahid, Mohammad Kazem ^a,b   Eftekhar, Mehrdad ^a,b  

^a HAKIM SABZEVARI UNIVERSITY   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fluvoxamine; Metacognitive therapy; Obsessive compulsive disorder

Indexed keywords

FLUVOXAMINE;

ADULT; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; TREATMENT RESPONSE;

EID: 77957870772     PISSN: 17358639     EISSN: 17359287     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Foa E, Franklin M, Moser J. Context in the clinic: how well do CBT and medications work in combination? Biol Psychiatry 2002; 52(10): 989-97.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.,text rev.).Washington, DC: Author; 2000.
3. Karno M, Golding J, Sorenson S, Burnam A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1998; 45(12): 1094-9.
4. Hanna GL. Demographic and clinical features of obsessive-compulsive disorder in child and adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34(1): 19-27.
5. Murray C, Lopez AD. Global burden of disease: A comprehensive assessment and morbidity from disease, injuries, and risk factors in 1990 and projected to 2020. Harvard: World Health Organization; 1996.
6. Abramowitz JS. Understanding and treating obsessive-compulsive disorder: A cognitive-behavioral approach. Mahwah, NJ: Lawrence Erlbaum Associates, Inc; 2006.
7. Abramowitz JS, Franklin ME, Foa EB. Empirical status of cognitive-behavioral therapy for obsessive-compulsive disorder: A meta-analytic review. Romanian J Cogn Behav Psychother 2002; 2: 89-104.
8. Rosa-Alcázar AI, Sánchez-Meca J, Gómez-Conesa A, Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev 2008; 28(8): 1310-25.
9. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8(1): 107-29.
10. Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin North Am 2000; 23(3): 643-56.
11. Clark DA. Cognitive Behavior Therapy for OCD. New York: The Guilford Press; 2004.
12. Fisher PL, Wells A. How effective are cognitive and behavioural treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Rese Ther 2005; 43(12): 1543-58. (Pubitemid 41472065)
13. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995; 166 (4): 424-43.
14. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60 (2): 101-6.
15. Walsh KH, McDougle CJ. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opin Pharmacother 2004; 5(10): 2059-67.
16. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: Management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65(14): 6-10.
17. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30 (3): 400-12.
18. Stanley MA, Turner SM. Current status of pharmacological and behavioral treatment of obsessive-compulsive disorder. Behav Ther 1995; 26(1):163-86.
19. Wells A. Metacognitive Therapy for Anxiety and Depression, New York: Guilford Press; 2009.
20. Wells A, Matthews G. Attention and emotion: A clinical perspective. Hove, UK: Erlbaum; 1994.
21. Wells A. Cognitive therapy of anxiety disorders: A practice manual and conceptual guide. Chichester, UK: Wiley; 1997.
22. Wells A. Emotional disorders and metacognition: Innovative cognitive therapy. Chichester, UK: Wiley; 2000.
23. Wells A. Meta-cognition and worry: A cognitive model of generalized anxiety disorder. Behav Cogn Psychother 1995; 23(3): 301-20.
24. Fisher PL, Wells A. Metacognitive therapy for obsessive-compulsive disorder: A case series. J Behav Ther Exp Psychiatry 2008; 39(2): 117-32. (Pubitemid 351434606)
25. Myers S, Fisher PL, Wells A. An empirical test of the metacognitive model of obsessive-compulsive symptoms: Fusion beliefs, beliefs about rituals, and stop signals. J Anxiety Disord 2009; 23(4): 436-42.
26. Irak M, Tosun A. Exploring the role of metacognition in obsessive-compulsive and anxiety symptoms. J Anxiety Disord 2008; 22(8): 1316-25.
27. Rees CS, van Koesveld KE. An open trial of group metacognitive therapy for obsessive-compulsive disorder. J behav Ther Exp Psychiatry 2008; 39(4): 451-8.
28. Agras WS, Berkowitz R. Clinical research and behavior therapy: Halfway there. Behav Ther 1980; 11(4): 472-87.
29. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, et al. Fluvoxamine for children and adolescents with obsessive compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 222-9.
30. Mundo E, Smeraldi E, Bellodi L. Fluvoxamine in the treatment of obsessive-compulsive disorder: A double-blind comparison with clomipramine. Eur Neuropsychopharmacolo 1996; 6(4): S4.
31. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006; 29(2): 553-84.
32. Rouillon F. A double-blind comparison of fluvoxamine and clomipramine in OCD. Eur Neuropsychopharmacolo 1998; 8(2): S260-S261.
33. First MB, Spitzer RL, Gibbon M, Williams, JBW. Structured Clinical Interview for DSM-IV Axis I Disorders- Patient edition (SCID-I/P, Version 2.0). New York: New York Psychiatric Institute, Biometrics Research Department; 1996.
34. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin L. Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, DC: American Psychiatric Association; 1997.
35. Zanarini MC, Skodol AE, Bender D, Dolan R, Sanislow C, Schaefer E, et al. The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses. J Personal Disord 2000; 14(4): 291-9.
36. Bakhtiari M. Mental disorders in patients with body dysmorphic disorder [MS dissertation]. Tehran, Iran University of Medical Sciences; 2000.
37. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale: Validity. Arch Gen Psychiatry 1989; 46(11): 1012-6. (Pubitemid 19278230)
38. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale: Development, use, and reliability. Arch GenPsychiatry 1989; 46(11): 1006-11.
39. nd ed. San Antonio, TX: Psychological Corporation; 1996.
40. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56(6): 893-7.
41. Woody SR, Steketee G, Chambless DL. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale. Behav Res and Ther 1995; 33(5): 597-605.
42. Taylor S. Assessment of obsessions and compulsions: Reliability, validity, and sensitivity to treatment effects. Clin Psychol Rev 1995; 15(4): 261-96.
43. Saboory S, Mehryar H, Ghareeb A. [Comparing the effectiveness of cognitive-behavioral techniques, clomipramine and their combination in the treatment of obsessive-compulsive disorder.] Iranian J Psychiat Clinl Psycho (Andisheh Va Raftar) 1998; 4(1): 25-34. Persian.
44. Fata L, Birashk B, Atef-Vahid MK, Dabson KS. [Meaning assignment structures/schema, emotional states and cognitive processing of emotional information: comparing two conceptual frameworks.] Iranian J Psychiat Clin Psychol (Andisheh Va Raftar) 2005; 11(3): 312-26. Persian.
45. Steketee G, Frost R, Bogart K. The Yale-Brown Obsessive Compulsive Scale: interview versus self-report. Behav Res Ther 1996; 34(8): 675-84. (Pubitemid 26316913)
46. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988; 8(1): 77-100.
47. Beck AT, Steer RA. Relationship between Beck Anxiety Inventory and the Hamilton Anxiety Rating Scale with anxious patients. J Anxiety Disord 1991; 5(3): 213-23.
48. Nedeljkovic M, Kyrios M. Confidence in memory and other cognitive processes in obsessive-compulsive disorder. Behav Res Ther 2007; 45(12): 2899-914.
49. Jacobson NS, Roberts LJ, Berns SB, McGlinchey JB. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol 1999; 67(3): 300-7.
50. Follette WC, Callaghan GM. The evolution of clinical significance. Clin Psychol: Sci Pract 2001; 8(4): 431-5.
51. Wise EA. Methods for analyzing psychotherapy outcomes: a review of clinical significance, reliable change, and recommendations for future directions. Journal of Personality Assessment 2004; 82(1): 50-9.
52. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman JF, Marazziti D, et al. Treatment non-response in OCD: Methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5(2): 181-91.
53. Cohen J. A power primer. Psychological Bulletin 1992; 112(1): 155-9.
54. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980; 136(1): 1-25.
55. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009; 374(9688): 491-9.
56. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5(1): 17-30.
57. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162(1): 151-61.